What is the role of crisaborole topical ointment 2% (Eucrisa) for the treatment of atopic dermatitis (eczema)?

Updated: Mar 13, 2019
  • Author: Brian S Kim, MD, MTR, FAAD; Chief Editor: William D James, MD  more...
  • Print
Answer

Crisaborole topical ointment 2% (Eucrisa) was approved by the FDA in December 2016 for mild-to-moderate atopic dermatitis in adults and children aged 2 years or older. The approval was based on two placebo-controlled trials (n=1522). Patients who received crisaborole achieved greater response with clear or almost clear skin after 28 days compared with vehicle-treated patients (P<.001).<ref>57</ref>


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!